1. Home
  2. MURA vs ZBAI Comparison

MURA vs ZBAI Comparison

Compare MURA & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • ZBAI
  • Stock Information
  • Founded
  • MURA 2013
  • ZBAI 2015
  • Country
  • MURA Ireland
  • ZBAI United States
  • Employees
  • MURA N/A
  • ZBAI N/A
  • Industry
  • MURA
  • ZBAI Professional Services
  • Sector
  • MURA
  • ZBAI Consumer Discretionary
  • Exchange
  • MURA Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • MURA 17.7M
  • ZBAI 17.3M
  • IPO Year
  • MURA N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • MURA $2.63
  • ZBAI $1.04
  • Analyst Decision
  • MURA Strong Buy
  • ZBAI
  • Analyst Count
  • MURA 4
  • ZBAI 0
  • Target Price
  • MURA $13.00
  • ZBAI N/A
  • AVG Volume (30 Days)
  • MURA 14.0M
  • ZBAI 134.7K
  • Earning Date
  • MURA 05-20-2025
  • ZBAI 03-13-2025
  • Dividend Yield
  • MURA N/A
  • ZBAI N/A
  • EPS Growth
  • MURA N/A
  • ZBAI N/A
  • EPS
  • MURA N/A
  • ZBAI N/A
  • Revenue
  • MURA N/A
  • ZBAI $670,000.00
  • Revenue This Year
  • MURA $34.35
  • ZBAI N/A
  • Revenue Next Year
  • MURA N/A
  • ZBAI N/A
  • P/E Ratio
  • MURA N/A
  • ZBAI N/A
  • Revenue Growth
  • MURA N/A
  • ZBAI 67.50
  • 52 Week Low
  • MURA $0.95
  • ZBAI $0.58
  • 52 Week High
  • MURA $4.74
  • ZBAI $2.50
  • Technical
  • Relative Strength Index (RSI)
  • MURA 56.94
  • ZBAI N/A
  • Support Level
  • MURA $2.48
  • ZBAI N/A
  • Resistance Level
  • MURA $2.66
  • ZBAI N/A
  • Average True Range (ATR)
  • MURA 0.12
  • ZBAI 0.00
  • MACD
  • MURA 0.04
  • ZBAI 0.00
  • Stochastic Oscillator
  • MURA 42.58
  • ZBAI 0.00

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: